louisiana glp-1 nausea class action Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus Lawsuit highlights the dangers of

GLP-1 treatments may be appropriate for patients who have struggled to lose weight through diet, exercise, or other medications alone especially when factors like insulin resistance, metabolic slowdown, or appetite dysregulation are involved

Individual results will vary as no two patients are the same

Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19

Breakthrough Cardiovascular-Outcome Data Expanding Prescriber Comfort and Payer Mandates The SELECT trials 20% reduction in major adverse cardiac events spurred the FDA to add a cardiovascular prevention indication to semaglutide in March 2024

Class Action Dont confuse MDL cases with class action lawsuits

The benefits of this approach go beyond just counteracting GLP-1 side effects